Clinical and experimental evidence suggests that the gut microbiota is crucial in the development of inflammatory bowel disease (IBD). The goal of this study was to identify intestinal microbiota in newly diagnosed IBD patients and compare it to healthy siblings who have the same genetic and environmental background as the patients, as well as healthy unrelated controls. For assessing the gut microbiota of participants’ stool samples, a molecular method targeting 16S ribosomal RNA was used. The examination of terminal restriction fragment length polymorphism was carried out. The study comprised newly diagnosed pediatric IBD patients, their unaffected healthy siblings, and unrelated healthy controls. The microbial diversity of IBD patients, healthy siblings, and healthy controls differed considerably. There was no discernible variation in microbial diversity between healthy siblings and healthy controls. When compared to healthy siblings and healthy controls, patients had lower levels of the species Eubacterium, Lactobacillus, Enterobacter, and Clostridium and higher levels of the genus Streptococcus, Prevotella, and Escherichia.

When compared to healthy siblings and healthy controls, newly diagnosed young IBD patients have considerably less varied microbiota and microbial composition.